EP1011654A4 - Methoden zur modulierung der zell aktivität - Google Patents

Methoden zur modulierung der zell aktivität

Info

Publication number
EP1011654A4
EP1011654A4 EP98941157A EP98941157A EP1011654A4 EP 1011654 A4 EP1011654 A4 EP 1011654A4 EP 98941157 A EP98941157 A EP 98941157A EP 98941157 A EP98941157 A EP 98941157A EP 1011654 A4 EP1011654 A4 EP 1011654A4
Authority
EP
European Patent Office
Prior art keywords
cellular activity
modulating cellular
modulating
activity
cellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98941157A
Other languages
English (en)
French (fr)
Other versions
EP1011654A1 (de
Inventor
Mathew Vadas
Jennifer Gamble
Pu Xia
Philip Barter
Kerry-Anne Rye
Brian Wattenberg
Stuart Pitson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Research and Development LLC
Original Assignee
Johnson and Johnson Pharmaceutical Research and Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Pharmaceutical Research and Development LLC filed Critical Johnson and Johnson Pharmaceutical Research and Development LLC
Publication of EP1011654A1 publication Critical patent/EP1011654A1/de
Publication of EP1011654A4 publication Critical patent/EP1011654A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
EP98941157A 1997-09-08 1998-09-08 Methoden zur modulierung der zell aktivität Withdrawn EP1011654A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO9002A AUPO900297A0 (en) 1997-09-08 1997-09-08 A method of modulating cellular activity
AUPO900297 1997-09-08
PCT/AU1998/000730 WO1999012533A1 (en) 1997-09-08 1998-09-08 A method of modulating cellular activity

Publications (2)

Publication Number Publication Date
EP1011654A1 EP1011654A1 (de) 2000-06-28
EP1011654A4 true EP1011654A4 (de) 2004-09-15

Family

ID=3803288

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98941157A Withdrawn EP1011654A4 (de) 1997-09-08 1998-09-08 Methoden zur modulierung der zell aktivität

Country Status (5)

Country Link
EP (1) EP1011654A4 (de)
JP (1) JP4570246B2 (de)
AU (2) AUPO900297A0 (de)
CA (1) CA2302838C (de)
WO (1) WO1999012533A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE323153T1 (de) * 1999-05-13 2006-04-15 Johnson & Johnson Pharm Res Sphingosinekinase
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
EP1195604A1 (de) * 2000-09-29 2002-04-10 Warner-Lambert Company Verfahren und Zusammensetzungen zum Screenen von Modulatoren von Lipidkinasen
US6610534B2 (en) * 2000-10-05 2003-08-26 Novartis Ag Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
CA2449487A1 (en) * 2001-06-07 2002-12-12 Pu Xia Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
AU2003215426A1 (en) * 2002-03-28 2003-10-13 Medvet Science Pty. Ltd. A method of modulating cellular activity
MXPA05003974A (es) * 2002-10-14 2005-08-03 Medvet Science Pty Ltd Un metodo de modulacion de la actividad celular epitelial mediante la modulacion de los niveles funcionales de la esfingosina cinasa.
EP1481680A1 (de) * 2003-05-30 2004-12-01 Aventis Pharma Deutschland GmbH Verwendung von S1P
AU2005253643B2 (en) * 2004-06-15 2011-12-01 Medvet Science Pty. Ltd. Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants
EP1765384A4 (de) * 2004-06-15 2009-07-08 Medvet Science Pty Ltd Verfahren zur modulierung der zellulären aktivität mit sphingosinkinase und mitteln dafür, und sphingosinkinase-varianten
CA2595469A1 (en) * 2005-01-21 2006-07-27 Pu Xia A method of treating cellular damage
WO2012015758A2 (en) 2010-07-30 2012-02-02 Saint Louis University Methods of treating pain
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766111A (en) * 1985-10-31 1988-08-23 Trustees Of Boston University Lipids with plasmin inhibitory properties
WO1988009345A1 (en) * 1987-05-20 1988-12-01 The Rogosin Institute Reconstituted hdl particles and uses thereof
US5190876A (en) * 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
CA2007507C (en) * 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
US5466716A (en) * 1990-12-31 1995-11-14 The Biomembrane Institute Liposomal trimethylsphingosine
WO1995003039A1 (en) * 1993-07-23 1995-02-02 The Biomembrane Institute N,n,n-trimethylsphingosine derivatives
ATE220549T1 (de) * 1994-12-29 2002-08-15 Univ California Verbindungen zur hemmung der ceramid vermittelten signalübertragung
US5677189A (en) * 1995-06-29 1997-10-14 Oncomembrane, Inc. Method for quantifying sphingosine and for diagnosing platelet activation
JPH09176083A (ja) * 1995-12-28 1997-07-08 Sankyo Co Ltd 新規化合物ｆ−１２５０９ａ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
AU757358B2 (en) 2003-02-20
AU8965898A (en) 1999-03-29
JP4570246B2 (ja) 2010-10-27
CA2302838C (en) 2010-03-16
AUPO900297A0 (en) 1997-10-02
EP1011654A1 (de) 2000-06-28
CA2302838A1 (en) 1999-03-18
JP2001515857A (ja) 2001-09-25
WO1999012533A1 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
PL330064A1 (en) Method of obtaining a catalyst
AP9500756A0 (en) Modulation of cellular activity
IL133822A0 (en) Aroylpiperazines for modulating sexual activity
GB9714227D0 (en) A method of scheduling calls
EP1039890A4 (de) Neue metformin salze und verfahren
PL335504A1 (en) Method of obtaining a catalytic composition
HU9702242D0 (en) Inozitol-glykanes of inzulin-like activity
ZA954437B (en) Method of operating of a radio system
EP1011654A4 (de) Methoden zur modulierung der zell aktivität
GB9702290D0 (en) A handset and method of operation thereof
GB2322767B (en) A method of transmitting call information
GB2327175B (en) Method of operating a cellular network
AU8742398A (en) Method of reducing a schiff base
ZA9810471B (en) New method
KR100714319B1 (ko) 파이프 하우스의 구축 방법
GB2325438B (en) Method of printing
GB2323279B (en) A method of preservation
AU2003204254A1 (en) A Method of Modulating Cellular Activity
GB2320911B (en) Method of making a mat
ZA957223B (en) Modulation of cellular activity
GB2327296B (en) Method of making a FET
GB9707251D0 (en) Novel method and compounds
GB2360805B (en) Method of completing a well
GB2332599B (en) Cellular communication system and method therefor
ZA9810044B (en) A method of construction

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000404

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JOHNSON & JOHNSON RESEARCH PTY LIMITED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH AND

A4 Supplementary search report drawn up and despatched

Effective date: 20040730

17Q First examination report despatched

Effective date: 20070725

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150106